Role of FXR in Hepatitis C Virus Replication
Maneno muhimu
Kikemikali
Tarehe
| Imethibitishwa Mwisho: | 08/31/2010 |
| Iliyowasilishwa Kwanza: | 09/22/2010 |
| Uandikishaji uliokadiriwa Uliwasilishwa: | 12/13/2011 |
| Iliyotumwa Kwanza: | 12/14/2011 |
| Sasisho la Mwisho Liliwasilishwa: | 12/13/2011 |
| Sasisho la Mwisho Lilichapishwa: | 12/14/2011 |
| Tarehe halisi ya kuanza kwa masomo: | 12/31/2009 |
| Tarehe ya Kukamilisha Msingi iliyokadiriwa: | 02/28/2010 |
Hali au ugonjwa
Uingiliaji / matibabu
Other: Guggulsterone
Awamu
Vikundi vya Arm
| Mkono | Uingiliaji / matibabu |
|---|---|
| Experimental: Guggulsterone One arm of 15 chronically HCV genotype one infected patients | Other: Guggulsterone Gugulipid®, natural extract from Commiphora mukul tree, containing 2.5% guggulsterone |
Vigezo vya Kustahiki
| Zama zinazostahiki Kujifunza | 18 Years Kwa 18 Years |
| Jinsia Inastahiki Kujifunza | Male |
| Hupokea Wajitolea wa Afya | Ndio |
| Vigezo | Inclusion Criteria: - Male patients infected by HCV genotype 1, with anti-HCV antibodies, non responders to at least one first line of therapy - Viral load > 1 x 105 UI/mL for more than 6 months and not treated for at least the last two months. - METAVIR score < F4 Exclusion Criteria: - Alcohol intake > 20 g/day - Immuno - suppressive therapy - Obesity BMI > 30, diabetes - Dyslipidemia requiring specific therapy - Liver cirrhosis or carcinoma - HIV or HBV co-infections - Other liver diseases - Major organ failures - Therapy with cytochrome P450 metabolized drugs |
Matokeo
Hatua za Matokeo ya Msingi
1. Evolution of the HCV plasmatic viral load while taking the FXR inhibitor guggulsterone. [One week]
Hatua za Matokeo ya Sekondari
1. Modification of the fraction of the circulating viral forms associated with apolipoprotein B [One week]
